Literature DB >> 22253459

Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.

Min Yi1, Funda Meric-Bernstam, Henry M Kuerer, Elizabeth A Mittendorf, Isabelle Bedrosian, Anthony Lucci, Rosa F Hwang, Jaime R Crow, Sheng Luo, Kelly K Hunt.   

Abstract

PURPOSE: Prediction of patients at highest risk for ipsilateral breast tumor recurrence (IBTR) after local excision of ductal carcinoma in situ (DCIS) remains a clinical concern. The aim of our study was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients with DCIS from our institution. PATIENTS AND METHODS: We retrospectively identified 794 patients with a diagnosis of DCIS who had undergone local excision from 1990 through 2007 at the MD Anderson Cancer Center (MDACC). Clinicopathologic factors and the performance of the Memorial Sloan-Kettering Cancer Center nomogram for prediction of IBTR were assessed for 734 patients who had complete data.
RESULTS: There was a marked difference with respect to tumor grade, prevalence of necrosis, initial presentation, final margins, and receipt of endocrine therapy between the two cohorts. The biggest difference was that more patients received radiation in the MDACC cohort (75% at MDACC v 49% at MSKCC; P < .001). Follow-up time in the MDACC cohort was longer than in the MSKCC cohort (median 7.1 years v 5.6 years), and the recurrence rate was lower in the MDACC cohort (7.9% v 11%). The median 5-year probability of recurrence was 5%, and the median 10-year probability of recurrence was 7%. The nomogram for prediction of 5- and 10-year IBTR probabilities demonstrated imperfect calibration and discrimination, with a concordance index of 0.63.
CONCLUSION: Predictive models for IBTR in patients with DCIS who were treated with local excision are imperfect. Our current ability to accurately predict recurrence on the basis of clinical parameters alone is limited.

Entities:  

Mesh:

Year:  2012        PMID: 22253459      PMCID: PMC3295558          DOI: 10.1200/JCO.2011.36.4976

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  36 in total

1.  Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial.

Authors:  A Ringberg; H Nordgren; S Thorstensson; I Idvall; H Garmo; B Granstrand; L G Arnesson; K Sandelin; A Wallgren; H Anderson; S Emdin; L Holmberg
Journal:  Eur J Cancer       Date:  2006-11-21       Impact factor: 9.162

2.  Why microscopy will remain a cornerstone of surgical pathology.

Authors:  Juan Rosai
Journal:  Lab Invest       Date:  2007-04-02       Impact factor: 5.662

Review 3.  How to build and interpret a nomogram for cancer prognosis.

Authors:  Alexia Iasonos; Deborah Schrag; Ganesh V Raj; Katherine S Panageas
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

4.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Authors:  Nina Bijker; Philip Meijnen; Johannes L Peterse; Jan Bogaerts; Irène Van Hoorebeeck; Jean-Pierre Julien; Massimiliano Gennaro; Philippe Rouanet; Antoine Avril; Ian S Fentiman; Harry Bartelink; Emiel J Th Rutgers
Journal:  J Clin Oncol       Date:  2006-06-26       Impact factor: 44.544

5.  SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening.

Authors:  Stefan O Emdin; Bengt Granstrand; Anita Ringberg; Kerstin Sandelin; Lars-Gunnar Arnesson; Hans Nordgren; Harald Anderson; Hans Garmo; Lars Holmberg; Arne Wallgren
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

6.  Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.

Authors:  Udo Rudloff; Edi Brogi; Julia P Brockway; Jessica I Goldberg; Milicent Cranor; Christine A Wynveen; Tatjana Nehhozina; Anne S Reiner; Sujata Patil; Kimberly J Van Zee
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

7.  Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.

Authors:  Tina W F Yen; Henry M Kuerer; Rebecca A Ottesen; Layla Rouse; Joyce C Niland; Stephen B Edge; Richard L Theriault; Jane C Weeks
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

8.  Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21.

Authors:  Edwin R Fisher; Joseph P Costantino; Marino E Leon; Hanna Bandos; Alka S Palekar; Bernard Fisher; Norman Wolmark
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

9.  Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group.

Authors:  Lorie L Hughes; Molin Wang; David L Page; Robert Gray; Lawrence J Solin; Nancy E Davidson; Mary Ann Lowen; James N Ingle; Abram Recht; William C Wood
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

10.  National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.

Authors:  Carmen J Allegra; Denise R Aberle; Pamela Ganschow; Stephen M Hahn; Clara N Lee; Sandra Millon-Underwood; Malcolm C Pike; Susan D Reed; Audrey F Saftlas; Susan A Scarvalone; Arnold M Schwartz; Carol Slomski; Greg Yothers; Robin Zon
Journal:  J Natl Cancer Inst       Date:  2010-01-13       Impact factor: 13.506

View more
  36 in total

1.  Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.

Authors:  Amy Trentham-Dietz; Mehmet Ali Ergun; Oguzhan Alagoz; Natasha K Stout; Ronald E Gangnon; John M Hampton; Kim Dittus; Ted A James; Pamela M Vacek; Sally D Herschorn; Elizabeth S Burnside; Anna N A Tosteson; Donald L Weaver; Brian L Sprague
Journal:  Breast Cancer Res Treat       Date:  2017-11-28       Impact factor: 4.872

Review 2.  Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions.

Authors:  Lawrence J Solin
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 3.  How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis?

Authors:  Habib Rahbar; Elizabeth S McDonald; Janie M Lee; Savannah C Partridge; Christoph I Lee
Journal:  Acad Radiol       Date:  2016-03-23       Impact factor: 3.173

Review 4.  Controversies in the Treatment of Ductal Carcinoma in Situ.

Authors:  Andrea V Barrio; Kimberly J Van Zee
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

5.  Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy.

Authors:  Shirin Muhsen; Andrea V Barrio; Megan Miller; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2017-08-21       Impact factor: 5.344

Review 6.  De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.

Authors:  E Shelley Hwang; Lawrence Solin
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

7.  Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Authors:  Patricia A Cronin; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2016-05-19       Impact factor: 5.344

Review 8.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

9.  Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?

Authors:  Devon Livingston-Rosanoff; Amy Trentham-Dietz; John M Hampton; Polly A Newcomb; Lee G Wilke
Journal:  Breast Cancer Res Treat       Date:  2021-06-15       Impact factor: 4.872

Review 10.  Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients.

Authors:  Chirag Shah; Frank A Vicini; Sameer Berry; Thomas B Julian; John Ben Wilkinson; Simona F Shaitelman; Atif Khan; Steven E Finkelstein; Neal Goldstein
Journal:  Am J Clin Oncol       Date:  2015-10       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.